COVID-19 UPDATE

Two days ago, EMA notified the start of a rolling review of data on the monoclonal antibody regdanvimab (Celltrion) for the treatment of COVID-19.

Two days ago, EMA notified the start of a rolling review of data on the monoclonal antibody regdanvimab (Celltrion) for the treatment of COVID-19.
February 26, 2021

Two days ago, EMA notified the start of a rolling review of data on the monoclonal antibody regdanvimab (Celltrion) for the treatment of COVID-19. These are great news, as now there are a total of 5 products being evaluated by EMA (3 vaccines and 2 treatments) which could be placed on the market during the following months, depending on the results of the evaluation.

The development of new tools to treat COVID-19 brings renewed hopes to fight against the pandemic. At Asphalion we are actively aiding in the development of vaccines and treatments for COVID-19, bringing our best to help all developers get their products ready to be authorized.

For further information you can contact us at: info@asphalion.com

Search News & Events

  • Filter by category

Share

Related news and events

NEW | MHRA announces new recognition routes

MHRA announces new recognition routes to facilitate safe access to new medicines with seven international partners.
The new recognition routes open additional options for the MHRA to bring cutting-edge medicines faster to UK patients by leveraging the expertise and decision-making of trusted regulatory partners.

WORLD ENVIRONMENT DAY 2023

On the occasion of World Environment Day, to encourage awareness and action for the protection of the environment, at Asphalion we have asked our team

For further information

If you are interested in our services, or wish to get in touch for a general enquiry, please contact us for more information.

Fill the form and we will contact you as soon as possible.

You can also follow us on:

Schedule a Free Meeting

Schedule here a free 30-minutes meeting with one of our consultants and tell us about your project, challenges or doubts. 

We will be happy to assist you!

Schedule a meeting